Published in J Clin Pathol on February 01, 2005
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene (2009) 8.01
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature (2012) 2.46
HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene (2011) 2.42
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med (2010) 1.81
The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J (2010) 1.41
Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr Drug Targets (2006) 1.33
Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med (2012) 1.33
Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med (2009) 1.28
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer (2010) 1.23
LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res (2011) 1.16
Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer (2006) 1.15
HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer (2005) 1.12
Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer (2010) 1.11
Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clin Cancer Res (2011) 1.10
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res (2013) 1.10
Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol (2013) 1.09
Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion. Oncogene (2010) 1.09
Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch (2010) 1.06
Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget (2014) 1.03
Molecular responses to hypoxia-inducible factor 1α and beyond. Mol Pharmacol (2014) 1.03
Gene expression and hypoxia in breast cancer. Genome Med (2011) 1.02
Differential hypoxic regulation of hypoxia-inducible factors 1alpha and 2alpha. Mol Cancer Res (2011) 0.99
Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer (2010) 0.97
Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells. J Biol Chem (2009) 0.97
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer (2005) 0.97
Nontranscriptional role of Hif-1α in activation of γ-secretase and notch signaling in breast cancer. Cell Rep (2014) 0.94
Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev (2008) 0.94
Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer. PLoS One (2013) 0.93
UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat Commun (2015) 0.92
Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch (2006) 0.91
Hypoxia induces differential translation of enolase/MBP-1. BMC Cancer (2010) 0.91
The role of [¹⁸F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors. Cancer Imaging (2011) 0.90
Expression of BNIP3 in invasive breast cancer: correlations with the hypoxic response and clinicopathological features. BMC Cancer (2009) 0.88
Expression of Hypoxia-inducible factor 1-α and vascular endothelial growth factor-C in locally advanced breast cancer patients. Clinics (Sao Paulo) (2011) 0.84
Role of Hypoxia-inducible factor-1 alpha and Survivin in colorectal carcinoma progression. Int J Colorectal Dis (2008) 0.84
HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. PLoS One (2013) 0.84
Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method. PLoS One (2013) 0.83
Expression of hypoxic markers and their prognostic significance in soft tissue sarcoma. Oncol Lett (2015) 0.83
Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast. Breast Cancer Res (2005) 0.82
Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Int (2010) 0.82
Grape seed extract inhibits VEGF expression via reducing HIF-1alpha protein expression. Carcinogenesis (2009) 0.82
Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer. Sci Rep (2016) 0.81
A systemic review of PET and biology in lung cancer. Am J Transl Res (2011) 0.81
Selective growth inhibition by glycogen synthase kinase-3 inhibitors in tumorigenic HeLa hybrid cells is mediated through NF-κB-dependent GLUT3 expression. Oncogenesis (2012) 0.80
Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells. Br J Cancer (2014) 0.80
Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma. Oncotarget (2015) 0.80
Impact of preoperative anemia on relapse and survival in breast cancer patients. BMC Cancer (2014) 0.79
Overexpression of carbonic anhydrase and HIF-1α in Wilms tumours. BMC Cancer (2011) 0.79
1α, 25-Dihydroxyvitamin D regulates hypoxia-inducible factor-1α in untransformed and Harvey-ras transfected breast epithelial cells. Cancer Lett (2010) 0.78
Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1α expression. Cell Oncol (Dordr) (2011) 0.78
Radiation Promptly Alters Cancer Live Cell Metabolic Fluxes: An In Vitro Demonstration. Radiat Res (2016) 0.78
The recent progress of the mechanism and regulation of tumor necrosis in colorectal cancer. J Cancer Res Clin Oncol (2015) 0.77
The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression. BMC Cancer (2013) 0.76
Cancer cells remodel themselves and vasculature to overcome the endothelial barrier. Cancer Lett (2014) 0.76
Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue. Head Neck Pathol (2009) 0.76
Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol (2014) 0.76
Silencing of hypoxia-inducible factor-1α promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWP9, VEGF and VEGFR2. Exp Ther Med (2016) 0.75
Hypoxia is a Key Driver of Alternative Splicing in Human Breast Cancer Cells. Sci Rep (2017) 0.75
Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer. Oncotarget (2016) 0.75
Implications of Hypoxia in Breast Cancer Metastasis to Bone. Int J Mol Sci (2016) 0.75
Angiogenin expression in human kidneys and Wilms' tumours: relationship with hypoxia and angiogenic factors. Int J Exp Pathol (2013) 0.75
CD63 and GLUT-1 Overexpression Could Predict a Poor Clinical Outcome in GIST: A Study of 54 Cases with Follow-Up. Gastroenterol Res Pract (2016) 0.75
Hypoxia-Inducible Factors and Cancer. Curr Sleep Med Rep (2017) 0.75
Clinicopathological significance of glucose transporter protein-1 overexpression in human osteosarcoma. Oncol Lett (2017) 0.75
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 23.83
Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 19.75
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol (1996) 15.20
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (1998) 9.56
Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst (2001) 8.57
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol (2001) 4.58
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst (2001) 4.27
Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res (1991) 4.12
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem (2000) 3.02
Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res (2001) 2.80
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res (2002) 2.57
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol (2004) 2.36
A novel quasi-viral agent, MaTu, is a two-component system. Virology (1992) 2.22
Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer (2001) 2.11
Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res (2001) 1.55
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer (2002) 1.43
The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat (2003) 1.36
Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res (2002) 1.35
Pathology and breast screening. Histopathology (1990) 1.21
Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol (2004) 1.17
Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology (2001) 1.13
Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat (2003) 1.12
Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet (2001) 1.10
Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci (1999) 1.09
Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res (2000) 1.04
Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha). J Cancer Res Clin Oncol (2002) 0.87
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst (2001) 4.27
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet (1992) 4.10
Efficacy of 'radioguided occult lesion localisation' (ROLL) versus 'wire-guided localisation' (WGL) in breast conserving surgery for non-palpable breast cancer: a randomised controlled multicentre trial. Breast Cancer Res Treat (2012) 3.99
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 3.94
Equilibrium properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.91
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Kinetic properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.33
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 3.27
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol (2000) 3.20
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (1998) 3.06
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst (2000) 2.77
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol (2004) 2.74
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol (2005) 2.70
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Gap junctional conductance is a simple and sensitive function of intracellular pH. Science (1981) 2.64
Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer (1993) 2.60
eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol (1999) 2.57
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52
Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer (1999) 2.47
Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet (1985) 2.44
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Doxorubicin gradients in human breast cancer. Clin Cancer Res (1999) 2.36
Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils. J Biol Chem (1989) 2.35
Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol (2001) 2.33
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev (1996) 2.26
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet (1999) 2.26
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res (1994) 2.21
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer (2003) 2.20
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol (2000) 2.18
Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol (1999) 2.17
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol (2000) 2.11
Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules. J Biol Chem (1998) 2.08
An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature (1988) 2.07
Radioactive seed localization for non-palpable breast cancer. Br J Surg (2013) 2.07
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst (1995) 2.07
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol (2000) 2.04
Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet (1993) 2.03
Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg (1998) 2.02
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer (2013) 2.01
Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat (1998) 1.97
Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene (2010) 1.93
Voltage dependence of junctional conductance in early amphibian embryos. Science (1979) 1.90
Relationships between vascularization and proliferation in invasive breast cancer. J Pathol (1999) 1.90
A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res (1994) 1.89
Selectivity of connexin-specific gap junctions does not correlate with channel conductance. Circ Res (1995) 1.84
Tissue distribution of the multidrug resistance protein. Am J Pathol (1996) 1.84
Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer (1987) 1.83
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood (1997) 1.82
Targeting gene expression to hypoxic tumor cells. Nat Med (1997) 1.82
Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol (1995) 1.81
bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer (1994) 1.81
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
A decade of postlaryngectomy vocal rehabilitation in 318 patients: a single Institution's experience with consistent application of provox indwelling voice prostheses. Arch Otolaryngol Head Neck Surg (2000) 1.79
The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer (2011) 1.77
[The sentinel node procedure: standard intervention for surgical treatment of breast cancer]. Ned Tijdschr Geneeskd (1998) 1.76
Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest (1995) 1.75
Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer (2010) 1.74
Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res (1992) 1.74
Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol (2004) 1.72
Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res (1994) 1.72
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol (2001) 1.71
Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat (1998) 1.70
Gating of gap junction channels. Biophys J (1984) 1.70
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer (1990) 1.69
Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol (2006) 1.67
Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer (2003) 1.67
Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol (1994) 1.66
hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer (2003) 1.65
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol (1998) 1.62
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer (1992) 1.62
Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res (2000) 1.60
New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene (2010) 1.60
Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance. Int J Cancer (1988) 1.59
Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. Histopathology (2003) 1.59
Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res (1993) 1.58
Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytometry DNA-histograms obtained from fresh material of 1,295 breast cancer cases. Hum Pathol (1996) 1.58